Jonathan R. Strosberg, MD

Jonathan Strosberg, MD, discusses safety data for 212Pb-DOTAMTATE in metastatic somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.

Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the future of using 177Lu-dotatate therapy to treat patients with neuroendocrine tumors.

​Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor at H. Lee Moffitt Cancer Center, discusses pasireotide as a potential treatment for patients with neuroendocrine tumors.

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.